Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Safety issues hit Janssen

Posted 14 October 2020

Safety concerns has hit yet another Covid vaccine developer with Janssen announcing it has put all its clinical trials on pause due to an "unexplained illness" in a participant.

The company is yet to reveal further details on the adverse event that has pushed it to delay development.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
How much to save the kid?
We paid a high price for our elderly so what about children
Special Report
Aust Covid Vaccine Tracker
UPDATES: Sanofi/GSK sign Statement of Intent with Gavi; Aust to import 3.8m vax doses
Approvals Action
Novartis' triplet inhaler ticked
First-in-class maintenance treatment of asthma